Doxifluridine
Based on 2 publication(s) in Google Scholar
Doxifluridine has anticancer activity. Doxifluidine is a 5-FU prodrug. Doxifluridine is a thymidine synthase inhibitor. Doxifluridine can enhance tumor inhibition by synergizing with a variety of drugs.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.44%
- CAS No.: 3094-09-5
- Formule: C9H11FN2O5
- Masse moléculaire:246.19
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Apoptosis Compound Library
HY-L003
-
FDA-Approved Drug Library
HY-L022
-
Anti-Cancer Compound Library
HY-L025
-
Drug Repurposing Compound Library
HY-L035
-
Nucleotide Compound Library
HY-L044
-
Anti-COVID-19 Compound Library
HY-L052
-
NMPA-Approved Drug Library
HY-L053
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
FDA-Approved Anticancer Drug Library
HY-L122
-
Human Metabolite Library
HY-L123
-
Off-patent Drug Library
HY-L141
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Anti-Cancer Approved Drug Library
HY-L213
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
3D Diverse Fragment Library
HY-L903
Publications Citing Use of MedChemExpress (MCE) Doxifluridine
More
Activité biologique
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| CCRF-CEM | IC50 |
2.2 x 10-5M
Compound: 1
|
Concentration required for the 50% inhibition of growth of CCRF-CEM human leukemia cells in culture
Concentration required for the 50% inhibition of growth of CCRF-CEM human leukemia cells in culture
|
[PMID: 7120290] |
| L1210 | IC50 |
3.0 x 10-6M
Compound: 5'-dFUrd
|
Inhibition of cell growth of L1210 mouse Leukemia cells
Inhibition of cell growth of L1210 mouse Leukemia cells
|
[PMID: 2967375] |
| L1210 | IC50 |
3.6 x 10-6M
Compound: 1
|
Concentration required for the 50% inhibition of growth of L1210 mouse leukemia cells in culture
Concentration required for the 50% inhibition of growth of L1210 mouse leukemia cells in culture
|
[PMID: 7120290] |
Doxifluridine (1-10 μM) inhibits angiogenesis by significantly inhibiting the expression of VEGF in FU-MMT-1 cells[1].
Doxifluridine (1-100 μM) slightly increases the expression of TSP-1 at low dose (1 μM) and inhibits the expression of TSP-1 at high dose (100 μM) in FU-MMT-1 cells[1].
Doxifluridine (100 μM) inhibits cell proliferation in HUVEC cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Doxifluridine (200 mg/kg; Intraperitoneal injection; Single dose) can inhibit thymidine synthase activity in DMH-induced colon cancer mice[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 3094-09-5
-
Appearance Solid
-
Masse moléculaire 246.19
-
Formule C9H11FN2O5
-
Color White to off-white
-
SMILES
O=C(N1)N([C@H]2[C@H](O)[C@H](O)[C@@H](C)O2)C=C(F)C1=O
-
Synonyms
Ro 21-9738; 5-Fluoro-5'-deoxyuridine; 5'-DFUR
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (2)
-
Journal Impact Factor
-
Most Recent
Solvant et solubilité
DMSO : ≥ 100 mg/mL (406.18 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
DMF : 100 mg/mL (406.18 mM; Need ultrasonic)
H2O : 20 mg/mL (81.24 mM; Need ultrasonic)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (10.15 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (10.15 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 27.5 mg/mL (111.70 mM); Clear solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
Pureté et documentation
-
Fiche technique (277 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Naganuma Y, et al. Metronomic doxifluridine chemotherapy combined with the anti-angiogenic agent TNP-470 inhibits the growth of human uterine carcinosarcoma xenografts. Cancer Sci. 2011 Aug;102(8):1545-52. [Content Brief]
[2]. Berne M, et al. Inhibition of thymidylate synthase after administration of doxifluridine in a transplantable colon carcinoma in the rat. Cancer Invest. 1988;6(4):377-83. [Content Brief]
[3]. Di Bartolomeo M, et al. Integrated treatment with doxifluridine and radiotherapy in recurrent or primary unresectable rectal cancer. A feasibility study. Tumori. 1999 May-Jun;85(3):211-3. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO / DMF | 1 mM | 4.0618 mL | 20.3092 mL | 40.6184 mL | 101.5459 mL |
| 5 mM | 0.8124 mL | 4.0618 mL | 8.1237 mL | 20.3092 mL | |
| 10 mM | 0.4062 mL | 2.0309 mL | 4.0618 mL | 10.1546 mL | |
| 15 mM | 0.2708 mL | 1.3539 mL | 2.7079 mL | 6.7697 mL | |
| 20 mM | 0.2031 mL | 1.0155 mL | 2.0309 mL | 5.0773 mL | |
| 25 mM | 0.1625 mL | 0.8124 mL | 1.6247 mL | 4.0618 mL | |
| 30 mM | 0.1354 mL | 0.6770 mL | 1.3539 mL | 3.3849 mL | |
| 40 mM | 0.1015 mL | 0.5077 mL | 1.0155 mL | 2.5386 mL | |
| 50 mM | 0.0812 mL | 0.4062 mL | 0.8124 mL | 2.0309 mL | |
| 60 mM | 0.0677 mL | 0.3385 mL | 0.6770 mL | 1.6924 mL | |
| 80 mM | 0.0508 mL | 0.2539 mL | 0.5077 mL | 1.2693 mL | |
| DMSO / DMF | 100 mM | 0.0406 mL | 0.2031 mL | 0.4062 mL | 1.0155 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Doxifluridine Related Classifications
HY-B0021 Related Classifications
Powered by Bioz